Canvas Dx™ by Cognoa

Cognoa

Canvas Dx™ by Cognoa

Canvas Dx has the potential to facilitate early diagnosis in children with ASD

FDA Breakthrough Device Designation

Do you know anyone using Canvas Dx™ by Cognoa?

Canvas Dx is a software as a medical device (SaMD) that has been authorized by the FDA to aid physicians in diagnosing autism spectrum disorder (ASD) in young children. This technology utilizes clinically validated artificial intelligence (AI) to assist in the diagnosis of ASD in children between the ages of 18 and 72 months who are at risk of developmental delay. The diagnostic process involves a parent/caregiver questionnaire, which is collected via a parent/caregiver facing app, two videos of the child interacting in their natural environment, recorded by the caregiver and analyzed by a specially-trained video analyst, and an HCP questionnaire completed by a physician who meets with the child and a parent/caregiver, collected via a healthcare provider portal.

Canvas Dx™ by Cognoa

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.


© 2023 Netspective Media LLC. All Rights Reserved.

Built on Feb 3, 2023 at 6:31am